PHILADELPHIA, Aug. 3, 2020 /PRNewswire-PRWeb/ -- ERT, the global leader in clinical endpoint data collection, today announced Jim Corrigan, President and CEO has been named one of the 100 most inspiring individuals in the life-sciences industry by PharmaVoice. Representing a broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how they have inspired their colleagues and affected positive changes in their organizations.
Jim is recognized for his dedication to supporting the industry during a time of significant change by exemplifying his core values which include ensuring employee well-being, instilling a culture of accountability and trust, and an unwavering focus on helping ERT's customers develop new treatments to improve the health of patients worldwide.
Jim has driven significant advancements in clinical trial methodologies that help global biopharmaceutical companies bring new treatments to patients through more efficient and effective data collection. Since COVID-19 stay-home mandates have interrupted some important clinical development programs, Jim has led ERT to accelerate its delivery of virtual data collection tools, ensuring patient safety and enabling clinical trial continuity regardless of their physical access to investigative sites.
"Jim's ability to inspire innovative thinking enables ERT to continually exceed customers' expectations and deliver the solutions they need to meet their complex needs," said Eran Broshy, Chairman of ERT's Board of Directors. "We're very proud of his accomplishments and applaud him – as well as all of the individuals being recognized – for this well-deserved recognition."
For more information, visit ert.com
About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what's next, so it can adapt without compromising standards.
Powered by the company's EXPERT® technology platform, ERT's solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs, and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.
For more information, go to ert.com or follow us on LinkedIn and Twitter.
SOURCE ERT
Share this article